September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

September 8, 2011

Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.

September 8, 2011

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

September 8, 2011

Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker's life science division.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

September 1, 2011

Branded drugs sold under their generic names at a reduced price can reduce retail and wholesale drug prices, according to a new report by the Federal Trade Commission.

September 1, 2011

GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

August 30, 2011

Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

August 30, 2011

A federal court has acted in favor of Teva Pharmaceutical Industries in the drug maker's patent infringement case against several generic drug companies seeking to market versions of its multiple sclerosis drug.

August 30, 2011

Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

August 29, 2011

The Food and Drug Administration has approved a new cancer drug made by Pfizer, the drug maker said.

August 29, 2011

A drug made by Pfizer and Bristol-Myers Squibb undergoing late-stage clinical trials was more effective than the generic drug warfarin in patients with atrial fibrillation, according to study results released Sunday.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


August 24, 2011

Par Pharmaceutical Cos. will acquire Anchen Pharmaceuticals for $410 million, Par said Wednesday.

August 23, 2011

The Food and Drug Administration has approved a chemotherapy drug made by Sandoz, the drug maker said Tuesday.

August 22, 2011

Prasco will market an authorized generic drug for urinary tract infections under an agreement with Shionogi, the company said Monday.

August 19, 2011

While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

August 19, 2011

Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

August 19, 2011

Generic drug maker Sandoz is suing Danish drug maker Novo Nordisk over a generic version of a drug used to treat diabetes, according to published reports.

August 18, 2011

Generic drug maker Sun Pharmaceutical Industries has received regulatory approval for a drug designed to treat an enlarged prostate.

August 16, 2011

Generic drug maker Perrigo reported sales of $2.76 billion and profits of $341 million in fiscal year 2011, according to an earnings report released Tuesday.

August 12, 2011

Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.

August 11, 2011

Drug maker Avanir Pharmaceuticals has filed suit against two generic drug makers seeking to launch versions of a drug used to treat pseudobulbar affect, which causes sudden, involuntary episodes of laughing and crying, and occurs secondary to numerous other neurological conditions.

August 11, 2011

The Food and Drug Administration has acknowledged the resubmission of an investigational Type 2 diabetes drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes.